Pharma bad boy Shkreli asks for prison release to fight COVID-19Pharma bad boy Martin Shkreli has asked authorities to let him out of prison, saying that he could Share XPharma bad boy Shkreli asks for prison release to fight COVID-19https://pharmaphorum.com/news/pharma-bad-boy-shkreli-asks-for-prison-release-to-fight-covid-19/
Current pharma model “not sustainable” during COVID-19, says Daiichi’s UK leadAt eyeforpharma Daiichi Sankyo’s Manuel Reiberg spoke about why the industry should look to make drugs more affordable Share XCurrent pharma model “not sustainable” during COVID-19, says Daiichi’s UK leadhttps://pharmaphorum.com/news/current-pharma-model-not-sustainable-during-covid-19-says-daiichis-uk-lead/
Gilead rescinds orphan status request for COVID-19 drugGilead has rescinded its request for orphan status for its potential COVID-19 antiviral remdesivir amid a furore over Share XGilead rescinds orphan status request for COVID-19 drughttps://pharmaphorum.com/news/gilead-rescinds-orphan-status-request-for-covid-19-drug/
Digital therapeutics formularies five years away in US, say payersPayers from the US may not include digital therapeutics products on formularies for another five years, according to Share XDigital therapeutics formularies five years away in US, say payershttps://pharmaphorum.com/news/digital-therapeutics-formularies-five-years-away-in-us-say-payers/
How would single payer healthcare in the US impact pharma? A pricing perspectiveThe US healthcare system is the most complicated amongst advanced industrialised countries. Health care provision is made up Share XHow would single payer healthcare in the US impact pharma? A pricing perspectivehttps://pharmaphorum.com/views-analysis-market-access/how-would-single-payer-healthcare-in-the-us-impact-pharma-a-pricing-perspective/
The biggest challenges facing rare disease pharma – and how the industry can tackle themAs Rare Disease day 2020 approaches, we take a look at the biggest challenges facing orphan drug developers Share XThe biggest challenges facing rare disease pharma – and how the industry can tackle themhttps://pharmaphorum.com/r-d/views-analysis-r-d/biggest-challenges-rare-disease/
Simple steps to better communicate NHS medicines spendLeela Barham says that there’s a communication problem when it comes to one of the most important and Share XSimple steps to better communicate NHS medicines spendhttps://pharmaphorum.com/views-analysis-market-access/simple-steps-better-communicate-nhs-medicines-spend/
ICER methods could be illegal in US, claims US think tankThe method used by the US Institute for Clinical and Economic Review (ICER) to gauge whether drugs are Share XICER methods could be illegal in US, claims US think tankhttps://pharmaphorum.com/news/icer-methods-could-be-illegal-in-us-claims-us-think-tank/
The 4 biggest pharma market access stories of 2019What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive Share XThe 4 biggest pharma market access stories of 2019https://pharmaphorum.com/views-analysis-market-access/the-4-biggest-pharma-market-access-stories-of-2019/
